Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The SEC appears to avoid going after the market infrastructure itself and I’ve detected in Gensler a tone of self preservation and unwillingness to go after politically “protected “ situations. Maybe not that he wouldn’t if presented with such a compelling and publicly obvious case that to ignore it would be untenable, but imo he isn’t plunging the SEC (and his own job security) into battles he is likely to lose or pay dearly for trying.
I’m sensing this not in a way that Gensler is fearful or in denial, but rather in a logical sense of you can’t do any good in the larger sense of the SEC job if you get cut down by taking on situations that will diminish you or take you out (I.e., you don’t spit into the wind.)
So it’s not that spoofing and other crimes don’t exist and aren’t being committed, as seen by the bank employees who got prosecuted, it’s easier to go after entities such as companies and individuals who aren’t part of the market system itself and where a lot of money is involved that might find it wetting many beaks, some small owl beaks and some hawk and big eagle beaks, but all birds of prey feeding off the retail mice as we try to traverse the Wall Street mazes that they construct for us!
Yes, a bit contorted and carried away perhaps but I don’t like being a mark in a rigged game.
It could have made the difference between allowing the institutions to accumulate positions, furthering the bullish sentiment and credibility, which in turn increases the share price, and so on, with an up listing likely along the way.
So with a billion or so shares outstanding, a $2-5 share price opportunity lost translates into as many billions market cap lost near term, and who knows where we could be now with the deserved boost in credibility!
Then why the LP derogatory posts? Are they ok but counter posts aren’t?
How about what you leave out:
Member of the Bush administration
Negotiator of NAFTA
Officer of biotech associations
Teacher of Federal Government employees
Loving daughter of cancer victim dedicated to help defeat cancer
Exactly!
Gentlemen, for this menial sin please say 10 Hail Mary and pray for mercy with remorse. I highly suggest you hold off on the Old Crow until after. Btw, I’m not a priest nor do I play one on TV
Go DCVax!!! Go nwbo!!!
MIA any day!
MIA any day!
Yes PM, I posted this after a glass of superior Bordeaux
Are Ripple and Thunderbird still around as cheap alternatives? Olde English 800?
Better still you quit cold turkey so your reflexes will be sharper to evade swinging golf clubs
I caught the 1 year Treasury at 5.15% today and a little boring to complement a lot of more dynamic equities isn’t a bad thing at 5%+ imo.
Scotty, have you really seen the light?
I hope so, and maybe you’ve already been accumulating shares for the climb up!
Maybe it’s already been discussed, however Merck canceled three Keytruda combo efforts as reported today, because they didn’t provide enough benefits. In short they weren’t working.
Might not the highly promising DCVax combo investigation by UCLA, with extraordinary looking preliminary findings, become much more important to Merck and the other PD1 product companies?
I’ve previously mentioned that the BPs, while seeing opportunities in the DCVax combo realm, may also see a potential existential threat to their oncology businesses if it turns out other DCVax combinations that don’t heavily benefit from PD1 elements, or a particular one like Keytruda, could leave them vulnerable.
Tricky and delicate but that’s why the C suite executes get paid the big bucks!
Austin Powers, international man of intrigue, very clever!
Oh behave!
Eggzactly!!!!!!!!
Talk to me Goose!
She was quite the babe back in the NAFTA days! And smart as a whip!!
One of these days Alice, to the moon!
Why indeed?
Overall there seems to be a crescendo of buzz around DCVax L and brain tumor actions dissatisfaction especially in the UK.
My spidey senses are tingling!
There’s also a growing awareness of the potentially huge impact DCVax platform could have across the various large cancer indications. While it’s exciting I also am worrying that BP might be realizing the potential existential threat to their big oncology drug empires.
DCVax platform potential could be humongous and I’m starting to think nwbo might see themselves not wanting to be acquired. Maybe more partnerships and/or licensing?
BP would probably prefer DCVax to be buried while they better position themselves perhaps?
If I remember correctly there was a decision made by nwbo to forgo the last 17 enrollments after the pause was lifted, because so much time had passed since the last previous enrollment and the expense and years of additional time to complete the treatment protocol and follow up wasn’t worth it.
We might still be waiting for TLD had the trial continued with enrollment of those last 17.
We’re smarter than the average bear, no boo boo?
I don’t know Yogi, Mr Ranger is going to be surprised
Does anyone remember?
You are correct sir!
Absolutely! There’s leadership that huffs and puffs and looks like they’re doing a lot of work, and then there’s leadership that plans ahead and makes choices that are so smart and leapfrogs the brute force approach by maximizing the commonality: one trial, one SAP, one core application, for multiple RA approvals!
Yes, getting a path to Orbis makes sense for the efficiency of effort and acceleration, and I think LP had this in mind along with the other benefits when they chose a large multinational trial with one SAP for four RAs.
It’s more complicated in that there have been other time dependent factors. One factor was effecting an anti takeover defense structure. There are probably others related to UK and EU pedigree and who knows the financial tax angles (not my expertise.)
Yea, verily, the signal is emerging from the noise.
When the signal gets strong enough the noise becomes effectively insignificant and effectively filtered out.
Stretching the analogy further, changing modulation from AM to FM is like resisting from the OTC to the NYSE/ASE/Nasdaq
Would open up inoperable tumors and possibly metastasized tumors, which would offer hope to reprieve so, so many patients and families from tough prognoses!
What a blessing that would be to so many!!!
Scotty, you don’t see the sp being carefully shaved down with precision?
The sp continues to be puppeteered imo.
Beginning to look like Xmas, no, that perhaps the MIA isn’t DCVax specific but maybe broader delay?
Stellarrrrr!!!! stellarrrrrr!!!!
Sorry, I was triggered into On The Waterfront mode
Imo, a merger or buyout would have nice positions available for those nwbo management who want to stay involved instead of moving on to a life of leisure or other activities. Dr MB for instance probably can educate many on all matter of intricacies of dendritic cell vaccine technology, in corporate and/or academia.
I think the issue is mismatch between expectations and the reality of what it takes to accomplish such a large trial and get through all the processes.
At the ASM LP spelled out pretty clearly the magnitude of the current effort, how every component needs to be accounted for and second sourceable, the enormity of the approval package, and the prerequisite of the MIA in the UK.
She indicated resources were assembling and proofing the application, so once MIA is approved (which is in MHRA’s court now, not waiting on nwbo) the MAA could be submitted asap.
That’s the reality regarding getting to UK approval, which I believe will be before the others, and so there we are.
The manipulation, naked shorting, AF hit pieces, and all the other damaging things haven’t helped but nwbo has persevered.
Bottom line is the platform science and the GBM treatment work and are breakthroughs where there is desperate need for better hope and OS with better QoL, and that can’t be swept under the rug.
Cut to the core, there is no reasonable doubt left that the phase 3 trial treatment protocol produced breakthrough results that are in fact best to date, with unmatched long lived survivors, period!
Anything short of approval, especially given DCVax’s unbeatable safety and quality of life, would be criminal imo!
Yes I must thank you as well for adding a new word to my vocabulary, and I used to read the dictionary for fun!
We’re playing with the big dogs now!
I trust she is making decisions she believes are in the best interests of commercializing DCVax L and I believe she’s a smart and tough leader who will get us through the process successfully.
We all try to figure things out without access to all the information and factors but when we do get a peak inside the kimono we like what we see !
Yes LP has gone to extraordinary measures to maintain control in the past, such as distributing the patents’ ownership such that an unwelcomed takeover would still be lacking complete access to the patents.
LP knows how to play the game since as Liam Neeson says, she has a certain set of skills
I don’t think so Scotty but I’m along for the whole ride so we’ll see!
Nah, it means the MMs decided to chip away at the sp a bit before letting it go up a little again so they can rinse and repeat.
Nwbo doesn’t need CRL for UK approval however it doesn’t hurt to have a credible alternative production site in case of disaster. Advent is sufficient for UK and EU.
Nonetheless CRL is a stabile contract manufacturer and could service the Americas including Canada, eh
Don’t fret, but review your boma making skills just to case
We know quite a bit and the timing bs is getting old:
Will never get to data lock
Will never get to TLD
Will never get peer reviewed journal article
Will not be a top tier journal
How’s that track record going?
Now it’s
No MIA
No MAA
Etc.
I bet we get MIA and MAA in the UK
I’m essentially at my average sp now, having averaged down when the sp was around 0.25 +\- with what for me is a significant number of shares. If the sp goes up a buck my investment is doubled+.
If the sp goes to zero I lose 100% of my investment and I will never again try to score a home run investment regardless of how good the risk reward looks, because this is the best risk reward I’ve ever seen imo.
OTH, every dollar to the upside multiplies my investment ($5 up = 5x investment, etc.) and if played right, I will never set foot in otc and small cap territory again, either.
In the meantime things are looking better than ever for DCVax approval, especially in the UK!
Scotty please, you know the sp is being manipulated like a Pinocchio puppet on strings, and is not closely connected to the value yet.
The time will come when the strings no longer control, and I wonder what the noses of the bulletin board mercenary puppets will look like?
Look in the mirror lately
It’s an independent and compelling view of dcvax stimulated and educated immune system attacking the tumors, and clearly distinguishes pseudo progression from progression!
Evidence that supports the efficacy of dcvax leading to increased OS and tumor necrosis.
If you think it’s a duck, and I think it’s a duck, and many neurologists think it’s a duck, and now many radiologists think it’s a duck, and long survived patients think it’s a duck, then it’s a mother quacking duck!
They do have ducks in the UK and know one when they see one